CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. 13, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated a Phase 2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced hormone-refractory prostate cancer (HRPC). Enrollment has commenced at San Bernardino Urological Associates Medical Group in San Bernardino, Calif., and the study is expected to expand to additional sites including the Dana-Farber Cancer Institute (DFCI), the Massachusetts General Hospital, and the Beth-Israel Deaconess Medical Center in Boston, Mass. This study marks the third solid tumor indication in which IPI-504 is being evaluated.
